SS-31
Also known as Elamipretide, MTP-131
Mitochondria-targeted peptide studied for mitochondrial disease.
- Category
- longevity
- Route
- subq
- Documented dose
- 5000–40000 mcg
- Typical frequency
- Once daily
- Cycle
- 4 weeks on, 4 off
- Half-life
- ~2 hours
- Common vial sizes
- 10 mg, 50 mg
- Regulatory status
- Investigational; not approved.
What it does
Also called elamipretide. It travels into the mitochondria and binds to cardiolipin, a fat that keeps the energy-producing machinery folded correctly. Think of it as tuning up the cell's power plants. What people look into it for: • Chronic fatigue and low energy tied to mitochondrial function • Heart and skeletal muscle performance • Recovery in older adults or after illness • Reducing oxidative stress and supporting healthy ageing It has been through real clinical trials for rare mitochondrial diseases, with mixed but promising results.
Mechanism
Binds cardiolipin on the inner mitochondrial membrane, improving electron transport efficiency.
Storage — lyophilised
Refrigerate 2-8C, protect from light.
Storage — reconstituted
Refrigerate 2-8C, use within ~28 days.
Reconstitution notes
Add 2 ml bacteriostatic water to a 50 mg vial for 250 mcg per unit.
Commonly stacked with
- MOTS-c
- NAD+
Commonly reported side effects
- Injection-site reactions
- Headache
- Dizziness
Contraindications noted
- Pregnancy or breastfeeding
Research notes
In clinical trials as elamipretide for primary mitochondrial myopathy.
Track this properly
Work out syringe units with the free calculator, or set up a full schedule in about a minute.
Reference information only, not medical advice. See our medical disclaimer.